DexCom Inc (DXCM) stock
DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3031% below fair value
$82.52+0.48 (+0.59%)
Close on Nov 18, 2026Market cap $30.78BP/E 32.5Yield –
DexCom revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
DexCom's revenue for the twelve months ending Sep 30, 2026 was $5.10B, up 13.0% year over year. For fiscal 2025 it was $4.66B, up 15.6% from the year before. Over ten years it grew 27.8% a year on average. The highest annual figure on record is $4.66B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.66B | +15.6% |
| FY2024 | Dec 31, 2024 | $4.03B | +11.3% |
| FY2023 | Dec 31, 2023 | $3.62B | +24.5% |
| FY2022 | Dec 31, 2022 | $2.91B | +18.8% |
| FY2021 | Dec 31, 2021 | $2.45B | +27.1% |
| FY2020 | Dec 31, 2020 | $1.93B | +30.5% |
| FY2019 | Dec 31, 2019 | $1.48B | +43.1% |
| FY2018 | Dec 31, 2018 | $1.03B | +43.6% |
| FY2017 | Dec 31, 2017 | $718.50M | +25.3% |
| FY2016 | Dec 31, 2016 | $573.30M | +42.6% |
| FY2015 | Dec 31, 2015 | $402.00M | +55.1% |
| FY2014 | Dec 31, 2014 | $259.20M | +62.0% |
| FY2013 | Dec 31, 2013 | $160.00M | +60.2% |
| FY2012 | Dec 31, 2012 | $99.90M | +30.9% |
| FY2011 | Dec 31, 2011 | $76.30M | +57.0% |
| FY2010 | Dec 31, 2010 | $48.60M | +63.7% |
| FY2009 | Dec 31, 2009 | $29.69M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.34B | +11.2% |
| Q2 FY2026 | Jun 30, 2026 | $1.31B | +13.1% |
| Q1 FY2026 | Mar 31, 2026 | $1.19B | +15.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.26B | +13.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.21B | +21.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.16B | +15.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.04B | +12.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.11B | +7.6% |
| Q3 FY2024 | Sep 30, 2024 | $994.20M | +2.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.00B | +15.3% |
| Q1 FY2024 | Mar 31, 2024 | $921.00M | +24.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.03B | +26.9% |
| Q3 FY2023 | Sep 30, 2023 | $975.00M | +26.7% |
| Q2 FY2023 | Jun 30, 2023 | $871.30M | +25.2% |
| Q1 FY2023 | Mar 31, 2023 | $741.50M | +17.9% |
| Q4 FY2022 | Dec 31, 2022 | $815.20M | +16.8% |
| Q3 FY2022 | Sep 30, 2022 | $769.60M | +18.4% |
| Q2 FY2022 | Jun 30, 2022 | $696.20M | +17.0% |
| Q1 FY2022 | Mar 31, 2022 | $628.80M | +24.5% |
| Q4 FY2021 | Dec 31, 2021 | $698.20M | +22.7% |
| Q3 FY2021 | Sep 30, 2021 | $650.20M | +29.8% |
| Q2 FY2021 | Jun 30, 2021 | $595.10M | +31.7% |
| Q1 FY2021 | Mar 31, 2021 | $505.00M | +24.7% |
| Q4 FY2020 | Dec 31, 2020 | $568.90M | +22.9% |
| Q3 FY2020 | Sep 30, 2020 | $500.90M | +26.4% |
| Q2 FY2020 | Jun 30, 2020 | $451.80M | +34.3% |
| Q1 FY2020 | Mar 31, 2020 | $405.10M | +44.4% |
| Q4 FY2019 | Dec 31, 2019 | $462.80M | +36.9% |
| Q3 FY2019 | Sep 30, 2019 | $396.30M | +48.6% |
| Q2 FY2019 | Jun 30, 2019 | $336.40M | +38.7% |
| Q1 FY2019 | Mar 31, 2019 | $280.50M | +52.1% |
| Q4 FY2018 | Dec 31, 2018 | $338.00M | +52.9% |
| Q3 FY2018 | Sep 30, 2018 | $266.70M | +44.5% |
| Q2 FY2018 | Jun 30, 2018 | $242.50M | +42.1% |
| Q1 FY2018 | Mar 31, 2018 | $184.40M | +29.6% |
| Q4 FY2017 | Dec 31, 2017 | $221.00M | +29.1% |
| Q3 FY2017 | Sep 30, 2017 | $184.60M | – |
| Q2 FY2017 | Jun 30, 2017 | $170.60M | – |
| Q1 FY2017 | Mar 31, 2017 | $142.30M | – |
| Q4 FY2016 | Dec 31, 2016 | $171.20M | – |
See a number that looks wrong?